Exjade and Eltrombopag olamine drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Exjade (deferasirox) and Eltrombopag olamine (eltrombopag olamine). Common drug interactions include nausea among females and pyrexia among males.
The phase IV clinical study analyzes what interactions people have when they take Exjade and Eltrombopag olamine. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.
What is Exjade?
Exjade has active ingredients of deferasirox. It is often used in iron overload. eHealthMe is studying from 29,456 Exjade users. Check the latest studies of Exjade.
What is Eltrombopag olamine?
Eltrombopag olamine has active ingredients of eltrombopag olamine. eHealthMe is studying from 3,901 Eltrombopag olamine users. Check the latest studies of Eltrombopag olamine.
13 people who take Exjade and Eltrombopag olamine together, and have interactions are studied.

What are the common drug interactions of Exjade and Eltrombopag Olamine, by gender? *:
female:
- Nausea (feeling of having an urge to vomit)
- Anxiety
- Blood bilirubin increased
- Blood pressure increased
- Diarrhoea
- Haemoglobin decreased
- Influenza
- Irritable bowel syndrome
- Platelet count increased
- Serum ferritin increased
male:
- Pyrexia (fever)
- Bone marrow failure
- Inflammation
- Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
- Staphylococcal infection (an infection with staphylococcus bacteria)
- Thrombocytopenia (decrease of platelets in blood)
- Vomiting
- Acute coronary syndrome (acute chest pain and other symptoms that happen because the heart does not get blood)
- Bronchopulmonary aspergillosis (lung disorder caused by aspergillus fungi)
- Cardiac failure
What are the common drug interactions of Exjade and Eltrombopag Olamine, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
- Bone marrow failure
- Pyrexia (fever)
- Vomiting
20-29:
n/a
30-39:
n/a
40-49:
n/a
50-59:
- Acute coronary syndrome (acute chest pain and other symptoms that happen because the heart does not get blood)
- Bronchopulmonary aspergillosis (lung disorder caused by aspergillus fungi)
- Cardiac failure
- Chimerism (fertilization of two separate ova by two sperm)
- Cough
- Dyspnoea (difficult or laboured respiration)
- Hyperthermia (body temperature greatly above normal)
- Inflammation
- Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
- Pyrexia (fever)
60+:
- Abdominal discomfort
- Abdominal distension
- Gastrointestinal disorder (functional problems of gastrointestinal tract)
- Nausea (feeling of having an urge to vomit)
- Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
- Platelet count decreased
- Seborrhoea (a disease of the sebaceous glands characterized by excessive secretion of sebum)
- Serum ferritin decreased
- Skin exfoliation (removal of the oldest dead skin cells)
- Tremor (trembling or shaking movements in one or more parts of your body)
What are the existing conditions these people have? *
- Thrombocytopenia (decrease of platelets in blood): 8 people, 61.54%
- Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 6 people, 46.15%
- Aplastic Anemia: 3 people, 23.08%
- Renal Impairment (severely reduced kidney function): 2 people, 15.38%
- Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 15.38%
- Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood): 2 people, 15.38%
- Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 2 people, 15.38%
- Aplasia Pure Red Cell (type of anaemia affecting the precursors to red blood cells but not to white blood cells): 2 people, 15.38%
- Platelet Disorder: 1 person, 7.69%
- Iron Deficiency: 1 person, 7.69%
* Approximation only. Some reports may have incomplete information.
Do you take Exjade and Eltrombopag olamine?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
- Exjade (29,456 reports)
- Eltrombopag olamine (3,901 reports)
Browse all drug interactions of Exjade and Eltrombopag olamine:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Exjade:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Eltrombopag olamine:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Exjade and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Eltrombopag olamine and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zRelated publications that referenced our studies
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
- Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
- Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
- Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
- Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
- Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
How the study uses the data?
The study uses data from the FDA. It is based on deferasirox and eltrombopag olamine (the active ingredients of Exjade and Eltrombopag olamine, respectively), and Exjade and Eltrombopag olamine (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Creon and Atenolol - 4 seconds ago
- Drug interactions of Septra Ds and Digoxin - 31 seconds ago
- Drug interactions of Banzel and Nystatin - 32 seconds ago
- Dyslipidaemia and Fall - 32 seconds ago
- Could Spiriva cause Skin Striae? - 38 seconds ago
- Could Mometasone Furoate cause Muscle Spasms? - 38 seconds ago
- Could Keflex cause Death? - 39 seconds ago
- Could Imuran cause Weight Loss? - 41 seconds ago
- Diuretic Therapy and Respiratory Acidosis - 48 seconds ago
- Drug interactions of Isoniazid and Carbamazepine - 56 seconds ago